Neoplasm by Special Category

This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (ass… (full text at CIViC)

PMID 23724913 · Shaw et al., 2013 · Open in CIViC

This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease. The study consisted of 343 patients with advanced or metas… (full text at CIViC)

PMID 25470694 · Solomon et al., 2014 · Open in CIViC

This trial enrolled 26 patients with anaplastic large cell lymphoma (ALCL). The groups received twice daily crizotinib at doses of either 165 or 280 mg/m2. 83% of the 165 mg/m2 ALCL patients had a com… (full text at CIViC)

PMID 28787259 · Mossé et al., 2017 · Open in CIViC

This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD… (full text at CIViC)

PMID 24478318 · Ou et al., 2014 · Open in CIViC

This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting t… (full text at CIViC)

PMID 27022118 · Solomon et al., 2016 · Open in CIViC

In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated … (full text at CIViC)

PMID 21933749 · Shaw et al., 2011 · Open in CIViC

A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer. The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174). … (full text at CIViC)

PMID 26466010 · 2015 · Open in CIViC

In this phase I/II study, 26 patients with relapsed/refractory ALK-positive ALCL were administered crizotinib orally twice daily in 28-day cycles as a single agent for an indefinite duration. Patients… (full text at CIViC)

PMID 28787259 · Mossé et al., 2017 · Open in CIViC

17 patients with ALK-positive advanced anaplastic large‐cell lymphoma (ALCL) enrolled in the PROFILE 1013 (NCT01121588) phase 1b single-arm, open-label, multi-centre study received crizotinib. ORR was… (full text at CIViC)

PMID 29352732 · Gambacorti-Passerini et al., 2018 · Open in CIViC

Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL). Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen,… (full text at CIViC)

PMID 21345110 · Gambacorti-Passerini et al., 2011 · Open in CIViC

Four adult ALK-rearranged anaplastic large cell lymphoma (ALCL) patients were resistant to chemotherapy after 3 or more lines of treatment. The patients were administered 250 mg crizotinib twice dail… (full text at CIViC)

PMID 23006951 · Foyil et al., 2012 · Open in CIViC

In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP. The patient attained a reduction in the target lesions by 14.2… (full text at CIViC)

PMID 25922291 · Le et al., 2015 · Open in CIViC

A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor … (full text at CIViC)

PMID 24687827 · Godbert et al., 2015 · Open in CIViC

A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL). ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to… (full text at CIViC)

PMID 24330038 · Wass et al., 2014 · Open in CIViC

Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed anaplastic lymphoma kinase gene … (full text at CIViC)

PMID 26942346 · Forde et al., 2016 · Open in CIViC

Authors report the ALK inactivation in ALK-positive ALCL induces an increase in BCL2 levels, which could contribute to therapeutic failures of current ALK targeted therapies. Their data strongly sugge… (full text at CIViC)

PMID 30679328 · Torossian et al., 2019 · Open in CIViC

26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potenti… (full text at CIViC)

PMID 19737969 · Lin et al., 2009 · Open in CIViC

84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential e… (full text at CIViC)

PMID 19737969 · Lin et al., 2009 · Open in CIViC

In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During … (full text at CIViC)

PMID 28586279 · Peters et al., 2017 · Open in CIViC

Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the anti… (full text at CIViC)

PMID 28183697 · Drilon et al., 2017 · Open in CIViC

In a phase 3 trial (CROWN, NCT03052608), a comparison of the selective third generation ALK inhibitor lorlatinib to the first generation ALK inhibitor crizotinib in 296 untreated ALK-fusion positive… (full text at CIViC)

PMID 33207094 · Shaw et al., 2020 · Open in CIViC

In a phase 2 trial, patients with NSCLC with ALK fusion received lorlatinib. In treatment-naive patients, ORR was 90.0% In patients with at least one previous ALK tyrosine kinase inhibitor, ORR were a… (full text at CIViC)

PMID 30413378 · Solomon et al., 2018 · Open in CIViC

A phase 2 trial of 228 ALK-positive NSCLC with or without previous chemotherapy treatment found lorlatinib to be effective in ALK inhibitor treatment-naive NSCLC as well as following treatment with on… (full text at CIViC)

PMID 30413378 · Solomon et al., 2018 · Open in CIViC

In a post hoc analysis of the phase 3 trial (CROWN, NCT03052608) comparing the selective third generation ALK inhibitor lorlatinib to the first generation ALK inhibitor crizotinib in ALK-fusion posit… (full text at CIViC)

PMID 35605188 · Solomon et al., 2022 · Open in CIViC

Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS… (full text at CIViC)

PMID 21642865 · Lee et al., 2011 · Open in CIViC

In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the tar… (full text at CIViC)

PMID 20940188 · Sequist et al., 2010 · Open in CIViC

In a stage IV lung adenocarcinoma patient, ALK I1171N was associated with acquired resistance to crizotinib monotherapy. An ALK gene rearrangement had been previously identified and was associated wi… (full text at CIViC)

PMID 27565911 · Johnson et al., 2016 · Open in CIViC

A case study of a 58 year old woman with ALK-rearranged NSCLC found the resistance mutation L1196M following treatment with crizotinib and alectinib. Treatment with ceritinib resulted in tumour regres… (full text at CIViC)

PMID 29796191 · Makuuchi et al., 2018 · Open in CIViC

In a prospective study (NCT01283516) of 130 cancer patients, non-small cell lung cancer patients (n=2) harboring a L1196M mutation in the ALK portion of the ALK rearrangement were associated with a 50… (full text at CIViC)

PMID 24670165 · Shaw et al., 2014 · Open in CIViC

This clinical study was conducted on patients harboring either ROS1 or ALK rearrangements, and were treated with Crizotinib. The two sub-protocols F(ALK rearrangements) and G(ROS1 rearrangements) had … (full text at CIViC)

PMID 35233056 · Mansfield et al., 2022 · Open in CIViC

BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM),… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

A case of metastatic renal cell carcinoma (RCC) is reported with a novel translocation t(X;9)(p11.23;p13.3) and RNA-seq identification of a putative corresponding fusion: VCP::TFE3. TFE3 fusion positi… (full text at CIViC)

PMID 36695651 · Kuentz et al., 2023 · Open in CIViC

Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.

PMID 25973082 · Tsai et al., 2015 · Open in CIViC

Tumor samples from the phase III trial of FOLFOX4
bevacizumab were assessed for VEGF165b and VEGFtotal by immunohistochemistry and scored relative to normal mucosal tissue. Low ratio of VEGF165b/VEG… (full text at CIViC)

PMID 23104894 · Bates et al., 2012 · Open in CIViC

Tumor samples with low ratio of VEGF165b/VEGFtotal treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.49; 95% CI, 0.26 to 0.93). The trend was not significant with p… (full text at CIViC)

PMID 23104894 · Bates et al., 2012 · Open in CIViC

We found that high VEGF expression (mean positive area > 5,000 pixels/×400 field) was associated with increased likelihood of achieving radiographic response (P = .024; Table 2).

PMID 18182667 · Sathornsumetee et al., 2008 · Open in CIViC

A meta analysis and systematic review of three trials with a total of 3748 breast cancer patients was undertaken to determine if VEGF-A plasma levels affected patient outcomes in response to bevacizum… (full text at CIViC)

PMID 25947646 · Santos et al., 2015 · Open in CIViC

In a clinical study including 12 patients already treated with bevacizumab, high levels of plasma VEGF-121 decrease the OS and the PFS (p = 0.0246 and p = 0.0295) compared to low level of expression.

PMID 29747600 · Martini et al., 2018 · Open in CIViC

Patients with high VEGF121and VEGF110 levels treated with bevacizumab compared to placebo show a trend toward improved PFS (HR 0.64, 95% CI, 0.47 to 0.88). The trend was not significant for patients w… (full text at CIViC)

PMID 27817944 · Miles et al., 2017 · Open in CIViC

In a clinical trials of 774 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab compared to placebo showed a trend toward improved OS (HR 0.72; 95% CI, 0.57 to 0.93… (full text at CIViC)

PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC

In VEGF-Axxxa high cases, the median OS of patients treated with taxane only (cohort A) was 26 months while the median OS of patients treated with paclitaxel/bevacizumab (cohort B) was 41 months: beva… (full text at CIViC)

PMID 24703319 · Pentheroudakis et al., 2014 · Open in CIViC

Nude mice were injected with VEGF165b-transfected LS174t colon cancer cells or control LS174t cells and treated with bevacizumab. VEGF165b expressing tumors grew faster than those not expressing VEGF1… (full text at CIViC)

PMID 18349829 · Varey et al., 2008 · Open in CIViC

Phase 2 trial of adult hepatocellular patients treated with sunitinib analyzed how baseline concentration of different soluble VEGF proteins predict overall survival (OS) and time to progression (TTP)… (full text at CIViC)

PMID 21787417 · Harmon et al., 2011 · Open in CIViC

The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusi… (full text at CIViC)

PMID 27069254 · Arber et al., 2016 · Open in CIViC

In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC